Cencora (NYSE:COR – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported $3.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.65 by $0.15, Briefing.com reports. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The business had revenue of $68.41 billion […]
Cencora (NYSE:COR – Get Free Report) had its price target boosted by stock analysts at Robert W. Baird from $275.00 to $277.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s target price would indicate a potential upside of 20.84% […]
Canada s second-largest bank by market capitalization said Tuesday the provision is related to talks with one U.S. regulator. Bank officials are in talks with two other regulators, and TD said the. -May 01, 2024 at 06:13 am EDT
- MarketScreener
North American Morning Briefing: Traders Wait for -2- morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
Revenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year
Second Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80
Adjusted Diluted EPS Guidance.
Cencora, Inc. (NYSE:COR – Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $239.05, but opened at $229.15. Cencora shares last traded at $226.95, with a volume of 445,751 shares changing hands. Analyst Upgrades and Downgrades A number of brokerages have issued reports on COR. Mizuho […]
Koninklijke Philips (NYSE: PHG) recently announced the receipt of FDA 510(k) approval for its Zenition 30 mobile C-arm. The approval is likely to make image-guided surgical procedures available to more patients at a lower cost in the United States.
Boston Scientific Corporation (NYSE: BSX) has been struggling due to unfavorable currency movement and macroeconomic woes. Strong competitors in the large medical device market also pose a tough challenge for Boston Scientific. The stock carries a Zacks Rank #4 (Sell) currently.
Top 10 best performing S&P 500 health care stocks of 2024 seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.